Ocular Therapeutix: The Drug Won, The Stock Lost, And That's The OpportunitySeeking Alpha · 1 day ago
Ocular Therapeutix, Inc. (OCUL) Discusses Progress and Regulatory Update on AXPAXLI NDA Filing TranscriptSeeking Alpha · 2 days ago
Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 WinMarketBeat · 5 days ago
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire · Oct 9, 2026
Ocular Therapeutix™ to Participate in October Scientific and Investor ConferencesGlobeNewsWire · Oct 1, 2026
Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 SuccessMarketBeat · Sep 22, 2026Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunctivitis.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 3, 2026 | -$0.40 | -$0.35 | Beat |
| May 5, 2026 | -$0.32 | -$0.41 | Miss |
| Feb 5, 2026 | -$0.33 | -$0.29 | Beat |
| Nov 4, 2025 | -$0.39 | -$0.37 | Beat |
| Aug 5, 2025 | -$0.35 | -$0.39 | Miss |
| May 5, 2025 | -$0.29 | -$0.37 | Miss |